RX Biosyent Inc

BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) is pleased to announce that its
subsidiary BioSyent Pharma Inc. has received Health Canada - Therapeutics
Products Directorate approval to market a new urgent care product. This is the
first of two products that were in-licensed from a European partner and
submitted to Health Canada in 2013 for approval.


The newly approved urgent care drug is supplied in a patented delivery system
that offers technical advantages over existing alternatives and will be used in
hospitals and acute care settings. These products will provide hospitals,
clinics, and healthcare professionals with improved patient safety as well as
operational efficiencies and will be marketed by BioSyent Pharma's Hospital
Division. It is anticipated that this new product will be launched in late 2014
or early 2015. "In anticipation of Health Canada approval our commercial team
has started the launch preparation process for this new product," said Rene
Goehrum, President and CEO of BioSyent. "We have already started discussions
with key opinion leaders and other decision makers in the Canadian hospital
market." Further product details will be disclosed closer to the launch date.


For a direct market quote (15 minutes delay) for the TSX Venture Exchange and
other Company financial information please visit www.tmxmoney.com.


About BioSyent Inc.

Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent
is a profitable growth oriented specialty pharmaceutical company which searches
the globe to in-license or acquire innovative pharmaceutical products that have
been successfully developed, are safe and effective, and have a proven track
record of improving the lives of patients and supporting the healthcare
professionals that treat them.


Once a product of interest has been found, BioSyent then acquires the exclusive
rights to the product and manages it through the Canadian governmental
regulatory approval process. Once approved, BioSyent markets the product
throughout Canada. 


At the date of this press release the Company had 13,801,195 shares issued and
outstanding. 


This press release may contain information or statements that are
forward-looking. The contents herein represent our judgment, as at the release
date, and are subject to risks and uncertainties that may cause actual results
or outcomes to be materially different from the forward-looking information or
statements. Potential risks may include, but are not limited to, those
associated with clinical trials, product development, future revenue,
operations, profitability and obtaining regulatory approvals.


The TSX Venture Exchange assumes no responsibility for the accuracy of this
release and neither approves nor disapproves of the same.


FOR FURTHER INFORMATION PLEASE CONTACT: 
BioSyent Inc.
Mr. Rene C. Goehrum
President and CEO
(905) 206-0013
investors@biosyent.com
www.biosyent.com

Biosyent (TSXV:RX)
過去 株価チャート
から 4 2024 まで 5 2024

Biosyent (TSXV:RX)
過去 株価チャート
から 5 2023 まで 5 2024